Bloomberg News

Wilex Rises 43% After Acquiring UCB’s Cancer Programs

January 09, 2009

Wilex AG, a German biotechnology company specialized in cancer drugs, jumped 43 percent in Frankfurt trading after the company announced that it will acquire UCB Pharma SA’s oncology portfolio in return for 1.82 million new shares.

The shares gained as much as 1.20 euros to 4 euros and traded at 3.70 euros at 9:12 a.m. in Frankfurt.

To contact the editor responsible for this story: Chris Malpass at cmalpass@bloomberg.net


Cash Is for Losers
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus